Swiss National Bank Akebia Therapeutics, Inc. Transaction History

Swiss National Bank

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.32 - $0.67 $125,787 - $263,366	-393,085 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$0.72 - $2.93 $20,376 - $82,919	28,300 Added 7.76%	393,085 $282,000
Q4 2021 Feb 08, 2022	BUY	$2.26 - $3.34 $64,861 - $95,858	28,700 Added 8.54%	364,785 $824,000
Q3 2021 Nov 08, 2021	BUY	$2.35 - $3.88 $34,310 - $56,648	14,600 Added 4.54%	336,085 $968,000
Q2 2021 Aug 06, 2021	BUY	$2.83 - $4.2 $21,791 - $32,340	7,700 Added 2.45%	321,485 $1.22 Million
Q1 2021 May 07, 2021	BUY	$2.92 - $5.06 $28,324 - $49,081	9,700 Added 3.19%	313,785 $1.06 Million
Q3 2020 Nov 09, 2020	BUY	$2.39 - $13.08 $123,802 - $677,544	51,800 Added 20.53%	304,085 $763,000
Q2 2020 Aug 05, 2020	BUY	$6.67 - $13.58 $682,341 - $1.39 Million	102,300 Added 68.21%	252,285 $3.43 Million
Q1 2020 May 08, 2020	BUY	$4.1 - $10.24 $8,610 - $21,504	2,100 Added 1.42%	149,985 $1.14 Million
Q4 2019 Feb 06, 2020	BUY	$3.16 - $6.73 $12,956 - $27,593	4,100 Added 2.85%	147,885 $935,000
Q3 2019 Nov 12, 2019	BUY	$3.55 - $5.4 $18,460 - $28,080	5,200 Added 3.75%	143,785 $564,000
Q1 2019 May 10, 2019	SELL	$5.41 - $8.73 $31,919 - $51,507	-5,900 Reduced 4.08%	138,585 $1.14 Million
Q4 2018 Feb 13, 2019	BUY	$5.39 - $9.15 $357,815 - $607,422	66,385 Added 85.0%	144,485 $799,000
Q1 2018 May 04, 2018	BUY	$9.53 - $15.68 $131,514 - $216,384	13,800 Added 21.46%	78,100 $744,000
Q4 2017 Feb 07, 2018	BUY	$14.24 - $19.59 $915,632 - $1.26 Million	64,300	64,300 $956,000

121

54.6M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $349M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.